Global Clinical Oncology Next Generation Sequencing Markets to 2030: Ion Semiconductor, Pyro, Synthesis, Real Time, Ligation, Reversible Dye Termination, & Nano-Pore Sequencing
May 06, 2021 05:33 ET
|
Research and Markets
Dublin, May 06, 2021 (GLOBE NEWSWIRE) -- The "Clinical Oncology Next Generation Sequencing Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
April 28, 2021 12:35 ET
|
Provectus Biopharmaceuticals Inc.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...
Florida Cancer Specialists & Research Institute Medical Oncologist Paresh Patel, MD Named 2021 FLASCO “Advocate of the Year”
April 20, 2021 13:20 ET
|
Florida Cancer Specialists
Fort Myers, Fla., April 20, 2021 (GLOBE NEWSWIRE) -- Pareshkumar Patel, MD, medical oncologist with Florida Cancer Specialists & Research Institute (FCS), is the recipient of the Florida Society...
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
March 30, 2021 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021 11:30 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 13, 2021 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft
December 01, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
November 10, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 27, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan
October 20, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its...